We and others have shown that Kir6.1/SUR2B expression is enriched in DA vessels and may represent a druggable target for treating PDA (Shelton et al., 2014, 2018; Yarboro et al., 2018). The gene discussed is KCNJ8; the disease is Patent ductus arteriosus.